Ambu A/S (OTCMKTS:AMBBY – Get Rating) was upgraded by stock analysts at DNB Markets from a "hold" rating to a "buy" rating in a research note issued to investors on Thursday, The Fly reports.
Separately, JPMorgan Chase & Co. increased their price target on Ambu A/S from 64.00 to 65.00 and gave the stock an "underweight" rating in a report on Wednesday, December 14th.
Get Ambu A/S alerts:Ambu A/S Price Performance
OTCMKTS:AMBBY opened at $14.55 on Thursday. The company has a 50 day simple moving average of $14.35 and a two-hundred day simple moving average of $11.99. Ambu A/S has a fifty-two week low of $8.08 and a fifty-two week high of $19.25.
About Ambu A/S
(Get Rating)
Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Visualisation. The Anaesthesia segment offers products from resuscitators, face masks, and laryngeal masks to the single use flexible intubation scope.
Recommended Stories
- Get a free copy of the StockNews.com research report on Ambu A/S (AMBBY)
- Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
- Has Workhorse Group Finally Hit Bottom?
- Target Offering A Rare Buying Opportunity After Earnings
- Rivian Gives Investors a Taste of the Anxiety Its Consumers Feel
- 3 High-Yield Dividend Stocks That Are Probably Not On Your Radar
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.
